TuisALK-B • CPH
add
ALK-Abello A/S
Vorige sluiting
kr 202,20
Dagwisseling
kr 203,20 - kr 207,00
Jaarwisseling
kr 130,70 - kr 237,60
Markkapitalisasie
41,57 mjd DKK
Gemiddelde volume
214,88 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CPH
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (DKK) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,73 mjd | 15,61% |
Bedryfskoste | 793,00 m | 6,02% |
Netto inkomste | 266,00 m | 56,47% |
Netto winsgrens | 15,35 | 35,36% |
Wins per aandeel | 1,20 | 50,00% |
EBITDA | 400,00 m | 40,35% |
Effektiewe belastingkoers | 32,32% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (DKK) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,24 mjd | 110,53% |
Totale bates | 9,06 mjd | 9,84% |
Totale aanspreeklikheid | 2,61 mjd | -9,08% |
Totale ekwiteit | 6,44 mjd | — |
Uitstaande aandele | 221,56 m | — |
Prys om te bespreek | 6,95 | — |
Opbrengs op bates | 11,32% | — |
Opbrengs op kapitaal | 14,70% | — |
Kontantvloei
Netto kontantverandering
| (DKK) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 266,00 m | 56,47% |
Kontant van bedrywe | 722,00 m | 59,38% |
Kontant van beleggings | -126,00 m | 88,35% |
Kontant van finansiering | -24,00 m | -103,67% |
Netto kontantverandering | 574,00 m | 1 639,39% |
Beskikbare kontantvloei | -136,62 m | 81,76% |
Meer oor
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
Gestig
1923
Webwerf
Werknemers
2 613
